Business Context and Reporting Period
NLS Pharmaceutics Ltd., a Swiss foreign private issuer, filed Form 6-K for January 2021 under Commission file number 001-39957. The filing was signed on January 29, 2021, by Alexander Zwyer, Chief Executive Officer.
The filing reports that on January 28, 2021, the company issued a press release announcing the pricing of a $20.0 million initial public offering.
Financial Metrics and Capitalization
- Offering: Initial public offering priced at an aggregate amount of $20.0 million.
- Revenue, profit, cash flow, margins, debt, and liquidity: The filing text does not provide financial statements or clear values for these items.
Material Changes Versus Prior Comparable Period
The filing does not provide comparative financial information. The material disclosed event is the pricing of the company’s $20.0 million initial public offering.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management discussion, risk factors, contingencies, or unusual operating items are provided in the filing text. The detailed terms of the offering are contained in Exhibit 99.1, but are not reproduced in the provided text.
Investor Verification Points
- Verify the final offering price per security, number and type of securities issued, and underwriting terms in Exhibit 99.1.
- Verify the expected gross and net proceeds and the company’s intended use of proceeds.
- Determine whether the offering closed and review any related dilution, lock-up, or listing provisions.
- Reconcile the offering proceeds with subsequent cash, liquidity, debt, and operating plans in later filings.